Description
Rengalin Pharmacodynamics
It was shown experimentally that the drug components modify the activity of ligand-receptor interaction of endogenous regulators with the corresponding receptors: antibodies to morphine (drug component) modify the activity of ligand-receptor interaction of endogenous regulators with opiate receptors; antibodies to histamine – with H1-histamine receptors; antibodies to bradykinin – with bradykinin receptors; herewith joint application of components leads to strengthening of anti-cough effect.
In addition to the anti-cough effect, the complex drug due to its components has anti-inflammatory, anti-edema, anti-allergic, antispasmodic (antibodies to histamine, antibodies to bradykinin) and analgesic effect (antibodies to morphine).
Due to modification of histamine-dependent activation of H1-receptors, bradykinin-dependent activation of B1 and B2-receptors, the complex preparation Rengalin selectively reduces excitability of the cough center of the medulla oblongata, inhibits central parts of the cough reflex. Inhibiting centers of pain sensitivity in thalamus, blocks transmission of pain impulses to cerebral cortex. Inhibits the flow of pain impulses from the periphery by reducing the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins, etc.). Unlike narcotic analgesics does not cause respiratory depression, drug dependence, does not have narcogenic and hypnotic effects.
It relieves symptoms of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm. Cures systemic and local symptoms of allergic reactions due to the effect on the synthesis and release of histamine and bradykinin from mast cells.
Indications
Acute and chronic respiratory diseases accompanied with cough and bronchospasm. Productive and non-productive cough in influenza and acute respiratory infections, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other infectious-inflammatory and allergic diseases of the upper and lower respiratory tract.
Contraindications .
Childhood under 3 years.
Increased individual sensitivity to the drug components.
Hereditary intolerance to fructose (due to the presence of maltitol).
Caution: diabetes mellitus.
Administration during pregnancy and lactation
Safety of using Rengalin in pregnant women and during breast-feeding period has not been studied. During pregnancy and breast-feeding the drug is used only if the expected benefits to the mother exceed the potential risk to the fetus and child. The benefit/risk ratio is determined by the attending physician.
Dosage and administration method
- Inside.
- Per oral intake – 1-2 teaspoons (5-10 ml) – out of meal.
- It is desirable to keep the solution in the mouth before swallowing for maximum effect of the drug.
- Use 1-2 teaspoons 3 times a day.
- Depending on the severity of the condition in the first three days, the frequency of intake may be increased to 4-6 times a day.
- The duration of therapy depends on the severity of the disease and is determined by the attending physician.
